Panagora Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Panagora Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,975	Closed	-$32K	–	2748
2021 Q1	$32K	Sell	5,975 -1,174	-16%	-$6.72K	﹤0.01%	2254
2020 Q4	$39K	Sell	7,149 -175	-2%	-$951	﹤0.01%	2088
2020 Q3	$58K	Sell	7,324 -6,538	-47%	-$57.2K	﹤0.01%	1977
2020 Q2	$139K	Sell	13,862 -4,604	-25%	-$28.9K	﹤0.01%	1677
2020 Q1	$50K	Hold	18,466	–	–	﹤0.01%	1882
2019 Q4	$22K	Buy	+18,466	New	+$19.7K	﹤0.01%	2027

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Panagora Asset Management's ADAP Position: Q2 2021 in Review

Panagora Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q2 2021, closing a stake of 5,975 shares — an estimated $32K sold.

Panagora Asset Management first reported a position in ADAP in Q4 2019 and held it in 6 quarters. The position peaked at $139K in Q2 2020. 82 funds tracked by Wall St. Rank hold ADAP as of Q2 2021.

Panagora Asset Management reported no remaining Adaptimmune Therapeutics position as of Q2 2021 after selling out during the quarter.
Panagora Asset Management sold 5,975 Adaptimmune Therapeutics shares in Q2 2021, an estimated $32K.
Panagora Asset Management first reported a position in Adaptimmune Therapeutics in Q4 2019 and held it in 6 quarters.
Panagora Asset Management's Adaptimmune Therapeutics position peaked at $139K in Q2 2020.
82 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2021.

Based on Panagora Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.